跳至主導覽 跳至搜尋 跳過主要內容

Recommendation for immune prophylaxis of respiratory syncytial virus infection in children

  • Ping Ing Lee*
  • , Yhu Chering Huang
  • , Chih Jung Chen
  • , Cheng Hsun Chiu
  • , Po Yen Chen
  • , Chun Yi Lu
  • , Ching Chuan Liu
  • , Nan Chang Chiu
  • , Hsin Chi
  • , Chien Yu Lin
  • , Chun Yi Lee
  • , Shuenn Nan Chiu
  • , Mei Jy Jeng
  • , Kuang Che Kuo
  • , Ren Bin Tang
  • , Yung Feng Huang
  • , Hui Hsien Pan
  • , Ming Fang Cheng
  • , Li Min Huang
  • , Ya Li Hu
  • Tzou Yien Lin
*此作品的通信作者
  • National Taiwan University
  • Chang Gung University
  • Veterans General Hospital-Taichung Taiwan
  • National Cheng Kung University
  • Mackay Memorial Hospital Taiwan
  • Hsinchu Municipal MacKay Children’s Hospital
  • Show-Chwan Memorial Hospital Taiwan
  • National Yang Ming Chiao Tung University
  • Cheng Hsin General Hospital
  • Fu Jen Catholic University
  • Veterans General Hospital-Kaohsiung Taiwan
  • Cathay General Hospital Taiwan

研究成果: 期刊稿件 › 文獻綜述 › 同儕審查

12 引文 斯高帕斯(Scopus)

摘要

Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age, and almost all children have been infected before 2 years of age. Monoclonal antibodies targeting RSV, such as palivizumab and nirsevimab, are accessible for preventing infection. A committee, consisting of experts in infectious diseases, cardiovascular diseases, and neonatal diseases in children, was assembled by the Pediatric Infectious Diseases Society of Taiwan. Collaborating with the Child Health Research Center at the National Health Research Institutes, Taiwan Pediatric Association, and Taiwan Society of Neonatology, the committee worked to formulate recommendations for immune prophylaxis against RSV infection in children. Palivizumab is recommended for the prevention of RSV infection in high-risk infants under 1 year old with one of the following (1) premature infants with a gestational age <33 weeks, (2) premature infants with a gestational age <35 weeks with chronic lung disease or (3) infants with hemodynamically significant CHD. Nirsevimab is recommended for the prevention of RSV infection in all infants <12 months. The recommendation is not intended as a sole source of guidance in the prevention of RSV infection in children. The provisions listed in this recommendation are comprehensive suggestions made by pediatric experts in Taiwan based on existing medical evidence. This recommendation should be subject to modification in light of additional medical research findings in the future, and these provisions should not be cited as a basis for dispute resolution.

原文英語
頁(從 - 到)288-293
頁數6
期刊Journal of Microbiology, Immunology and Infection
卷58
發行號3
DOIs
出版品狀態已出版 - 06 2025

文獻附註

Publisher Copyright:
© 2025

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Recommendation for immune prophylaxis of respiratory syncytial virus infection in children」主題。共同形成了獨特的指紋。

引用此